PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Connect Tissue Res. Author manuscript; available in PMC 2010 July 19.
Published in final edited form as:
PMCID: PMC2905683
NIHMSID: NIHMS212376

Age and Skeletal Sites Affect BMP-2 Responsiveness of Human Bone Marrow Stromal Cells

Abstract

Bone marrow stromal cells (BMSCs) contain osteoprogenitors responsive to stimulation by osteogenic growth factors like bone morphogenetic proteins (BMPs). When used as grafts, BMSCs can be harvested from different skeletal sites such as axial, appendicular and orofacial bones, but the lower therapeutic efficacy of BMPs on BMSCs-responsiveness in humans compared to animal models may be partly due to effects of skeletal site and age of donor. We previously reported superior differentiation capacity and osteogenic properties of orofacial BMSCs relative to iliac crest BMSCs in same individuals. This study tested the hypothesis that recombinant human BMP-2 (rhBMP-2) stimulates human BMSCs differently based on age and skeletal site of harvest. Adult maxilla, mandible and iliac crest BMSCs from same individuals and pediatric iliac crest BMSCs were comparatively assessed for BMP-2 responsiveness under serum-containing and serum-free insulin-supplemented culture conditions. Adult orofacial BMSCs were more BMP-2-responsive than iliac crest BMSCs based on higher gene transcripts of alkaline phosphatase, osteopontin and osteogenic transcription factors MSX-2 and Osterix in serum-free insulin-containing medium. Pediatric iliac crest BMSCs were more responsive to rhBMP-2 than adult iliac crest BMSCs based on higher expression of alkaline phosphatase and osteopontin in serum-containing medium. Unlike orofacial BMSCs, MSX-2 and Osterix transcripts were similarly expressed by adult and pediatric iliac crest BMSCs in response to rhBMP-2. These data demonstrate that age and skeletal site-specific differences exist in BMSC osteogenic responsiveness to BMP-2 stimulation and suggest that MSX-2 and Osterix may be potential regulatory transcription factors in BMP-mediated osteogenesis of adult orofacial cells.

Keywords: Bone morphogenic proteins, age, skeletal site, stem cells

Introduction

Skeletal homeostasis is maintained by bone marrow stromal cells (BMSCs), a major source of osteoprogenitor cells for bone renewal based on their multipotent properties and capacity to respond to stimulation by hormones and growth factors [13]. Bone morphogenetic proteins (BMPs) are potent osteogenic stimulants; they belong to the transforming growth factor-β (TGF-β) super family that promote osteoblast differentiation in vitro and play key roles in bone formation in vivo [46].

In adults, BMP-2 and BMP-7 have broadest orthopedic and dental applications because in vitro studies have shown they stimulate the entire process of stem cell differentiation into mature osteoblasts. Specifically, BMP-2 increases in vitro alkaline phosphatase activity and gene expression of osteopontin and osteocalcin in human, rat and mouse BMSCs [68]. In vivo studies have also shown that a combination of BMP-2 and retinoic acid significantly increased healing of mouse calvarial defects within a short time [9] and ex vivo-expanded human BMSCs isolated during pelvic or femoral osteotomy exhibited higher in vivo bone forming capacity after exposure to BMP-2 [1012].

BMPs appear to predominantly control growth and differentiation of cartilage and bone during embryonic development [4, 13], and age-related differences in response of canine BMSCs to BMP-2 have been described [14]. Using cells isolated from human iliac crest and rodent femurs, we have previously shown that human BMSCs exhibit lower in vitro osteogenic response to BMP-2 compared to rodents [15]. Additionally, we have identified skeletal site-specific differences in osteogenic properties of human orofacial and axial BMSCs [16]. However, it is still unclear whether disparate BMSC responses to BMP are specie, age or skeletal site dependent. Also, the underlying mechanisms of disparate response of human BMSCs to BMP-2 stimulation have not been clearly defined.

The present study tested the hypothesis that BMP-2 stimulation of human BMSCs is dependent on age and skeletal site of harvest. Using human BMSCs isolated from pediatric iliac crest and adult maxilla, mandible and iliac crest, we provide evidence that age and skeletal site-specific differences exist in BMP-2-induced osteogenesis of BMSCs.

Materials and Methods

Bone Marrow Stromal Cell Isolation and Culture Conditions

Trabecular bone samples were collected from four healthy adult volunteers at the Hospital of the University of Pennsylvania, and marrow aspirates from four pediatric patients at Children’s Hospital of Philadelphia, Philadelphia PA. Written informed consent was obtained under two Institutional Review Board-approved protocols. Mononucleated cells were harvested from maxilla and mandible (orofacial) trabecular bone samples and iliac crest (axial) marrow of adult donors; and also from iliac crest marrow aspirates of pediatric donors. Primary cultures of BMSCs were established from all samples in α-modified minimum essential medium (α-MEM) supplemented with 20% fetal bovine serum (FBS) (Equitech Bio, Kerville, TX), 100 U/ml penicillin, 100 mg/ml streptomycin sulfate and 2 mM glutamine (all reagents from Gibco, Invitrogen, Carlsbad, CA unless otherwise stated) incubated at 37°C in a humidified atmosphere of 5% CO2 and air as previously described [16]. Sub-confluent primary BMSCs were either stored in liquid nitrogen or further expanded in culture so that lower passage BMSCs (passages 2 to 4) were used for all experiments.

Treatment of Bone Marrow Stromal Cells With Recombinant Human BMP-2 (rhBMP-2)

In separate 6-well plates, early passage maxilla and mandible (orofacial) and iliac crest (axial) BMSCs were seeded at 1 × 104 cells/cm2 in growth medium as described above. Twenty four hours after seeding, growth medium was changed to osteogenic medium consisting of α-MEM supplemented with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin sulfate, 2 mM glutamine and 0.35 mM L-ascorbic acid 2-phosphate (Wako Pure Chemical Industries, Ltd., Japan). On day 4, BMSCs were exposed to six different culture conditions as follows: 1) osteogenic medium supplemented with or 2) without 100 ng/ml of rhBMP-2 (R&D Systems, Minneapolis, MN); 3) serum-free insulin containing osteogenic medium in which FBS was replaced with 0.1 % ITS Universal Culture Supplement Premix (BD Biosciences, San Jose, CA) with or 4) without 100 ng/ml rhBMP-2; and 5) serum-free osteogenic medium in which FBS was replaced with 1.25 % bovine serum albumin (Sigma-Aldrich, St. Louis, MO) with or 6) without 100 ng/ml rhBMP-2. The cells were maintained in their respective culture conditions with daily medium changes until analyzed on day 7 (i.e. 3 days after exposure to rhBMP-2).

Analysis of Effect of Culture Conditions on rhBMP-2 –induced Proliferation of Bone Marrow Stromal Cells

After 3-day BMP-2 treatment under the six culture parameters listed above, actively proliferating cells were assessed using WST-1 cell viability assay (Roche Applied Science, Indianapolis IN) following manufacturer’s protocol as previously described [17]. Number of actively proliferating cells was directly proportional to absorbance at 450 nm measured with Multiskan MCC microplate reader (Thermo Fisher Scientific, Waltham, MA). Based on this preliminary WST-1 cell survival results that showed no BMP-2 –associated differences among the culture conditions, only serum-containing and insulin-containing culture parameters (i.e. #1 to 4 above) were further evaluated in this study.

Analysis of Live Bone Marrow Stromal Cells and Alkaline Phosphatase Activity

In separate experiments for assessment of alkaline phosphatase activity, numbers of viable cells were estimated using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS, Promega Corp., Madison, WI) before harvesting the cells for alkaline phosphatase analysis. Briefly, BMSCs were washed once with Hank’s Buffered Salt Solution (HBSS), before adding 200 μl MTS reagent (1:10 volume/volume in phenol red-free α-MEM). Cells were incubated for 15 min at 37°C in a humidified, 5% CO2 atmosphere. MTS-containing medium from each well was transferred to 96-well plates to measure absorbance at 490 nm. Subsequently, BMSCs were washed twice with HBSS, lysed in 10% Triton X-100 and kept at 4°C. Alkaline phosphatase activity was determined kinetically by monitoring conversion of p-nitrophenyl phosphate to p-nitrophenol over 10-minutes as previously described [7]. Alkaline phosphatase activity was calculated as nM p-nitrophenol released per minute, further normalized to live cell number to obtain specific alkaline phosphatase activity/cell.

Real-Time PCR Analysis of rhBMP-2-Treated Bone Marrow Stromal Cells

BMSCs from the different culture conditions were harvested using Trizol reagent (Invitrogen, Carlsbad, CA) and total RNA was isolated following manufacturer’s protocol. 2 μg of total mRNA was converted into cDNA using oligo (dT) and the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA). Real-time PCR reaction was carried out in ABI 7300 Real-Time PCR System using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and gene-specific primers were designed with the Primer Express software (Applied Biosystems, Foster City, CA). The following primer sequences were used: human alkaline phosphatase, forward, 5′-CCGTGGCAACTCTATCTTTGG-3′, reverse, 5′-GATGGCAGTGAAGGGCTTCTT-3′; human osteopontin, forward, 5′-TGGAAAGCGAGGAGTTGAATG-3′, reverse, 5′-CATCCAGCTGACTCGTTTCATAA-3′; human RUNX2/CBFA1, forward, 5′-TCAGCACCACAAGCCACTTC-3′, reverse, 5′-GGTCGGAGAATGGGTTCAGTT-3′; human Osterix, forward, 5′-ACTCACACCCGGGAGAAGAA-3′, reverse, 5′-GGTGGTCGCTTCGGGTAAA-3′ and human MSX-2, forward, 5′-GCACCCTGAGGAAACACAAG-3′, reverse, 5′-CGAGGAGCTGGGATGTGGTA-3′. TATA binding protein (TBP), forward, 5′-GGAGCTGTGATGTGAAGTTTCCTA-3′, reverse, 5′-CCAGGAAATAACTCTGGCTCATAAC-3′ was used as normalizing control. Results were expressed as relative fold change using the ΔΔCt method (Applied Biosystems, Foster City CA).

Statistical Analysis

Results from triplicate experiments from each subject were expressed as mean ± standard deviation. BMP-2 effects on BMSCs were presented as fold change or percent change relative to control untreated BMSCs. Data analysis was by two-way analysis of variance (ANOVA) followed by post-hoc comparisons with Holm-Sidak test using SigmaStat 3.1 statistical package (Systat Software, Inc., Chicago, IL). Statistical significance was set at P < 0.05.

Results

Skeletal site and age-related differences in rhBMP-2-induced alkaline phosphatase expression

BMSCs isolated from four pediatric (ages 6 to 9 years) and four adult (ages 17 to 25 years) patients (Table 1) were tested for age and skeletal site-dependent response to BMP-2 stimulation under different culture conditions. There were no significant differences in proliferation of adult (Figure 1) or pediatric (data not shown) BMSCs among the different culture conditions when rhBMP-2 was added to the culture media. This confirmed that 100 ng/ml rhBMP-2 was conducive to cell survival irrespective of culture condition and the BMSCs continued proliferating to confluent monolayer by day 7 with or without BMP-2 stimulation (data not shown). Adult BMSCs from maxilla and mandible were more responsive to BMP-2 stimulation based on higher alkaline phosphatase mRNA in 2 of 4 patients while iliac crest BMSCs from all 4 adult patients were unresponsive (Figure 2A). In contrast, 3 of 4 pediatric iliac crest BMSCs responded to BMP-2 stimulation like adult maxilla and mandible BMSCs by displaying comparatively similar increase in alkaline phosphatase mRNA (Figure 2B) and activity (data not shown). Further testing of additional pediatric BMSCs (n =12) in our cell library confirmed a statistically significant increase in alkaline phosphatase activity by pediatric BMSCs in response to BMP-2 (p < 0.01) (Figure 2C). These alkaline phosphatase results indicate skeletal site and age-related differences in BMSCs responsiveness to BMP-2 stimulation. Adult maxilla, mandible and pediatric iliac crest BMSCs demonstrated similar BMP-2 responsiveness while adult iliac crest BMSCs were less responsive.

Figure 1
BMP-2 effects on adult BMSC proliferation unaffected by variable culture conditions
Figure 2
BMP-2 stimulated alkaline phosphatase expression in adult orofacial and pediatric iliac crest BMSCs in serum-containing medium
Table 1
Characteristics of BMSC donors

Insulin-Containing Culture Affects Alkaline Phosphatase Levels in rhBMP-2–Treated Bone Marrow Stromal Cells

We have previously reported that switching culture conditions to serum-free insulin-containing medium enhanced BMP-induced early osteogenic response of adult human femoral BMSCs (4). Similarly, insulin-mediated increase in alkaline phosphatase activity in response to BMP-2 was recapitulated in pediatric iliac crest BMSCs (Figure 3A). To further define this response, we evaluated effect of age and skeletal sites on insulin-mediated BMP-2 responsiveness of adult BMSCs by real time PCR. Higher levels of alkaline phosphatase mRNA transcripts were displayed by 3 of 4 adult orofacial BMSCs compared to iliac crest cells (Figure 3B). Despite individual variability, insulin effect on adult BMSCs response to BMP-2 appeared to be skeletal site-dependent. Adult iliac crest BMSCs from 3 of 4 donors (Figure 3B) did not respond as pediatric iliac crest cells, which further suggests that insulin effect on BMP-2 response may be age-dependent.

Figure 3
Serum-free insulin-containing culture condition enhanced BMP-2-induced expression and activity of alkaline phosphatase in pediatric iliac crest and adult orofacial BMSCs

Skeletal Site and Age-Related Differences in BMP-Induced Osteopontin Expression

In serum-containing medium, osteopontin gene was generally poorly expressed by adult iliac crest and 3 of 4 maxilla and mandible BMSCs in response to BMP-2 stimulation (Figure 4A). However, pediatric iliac crest unlike adult iliac crest BMSCs were slightly more BMP-2-responsive (Figure 4B); which further supports possible age-related effects. Additionally, switching to insulin-containing medium enhanced osteopontin gene expression in adult maxilla and mandible BMSCs (Figure 4C) similar to the alkaline phosphatase response presented in Figure 3B. This further confirms that insulin effect on BMSC BMP-2 responsiveness is apparently skeletal site-dependent.

Figure 4
BMP-2-induced osteopontin expression in orofacial adult BMSCs is affected by culture conditions

Effect of rhBMP-2 on Activation of Osterix and MSX-2

Assessment of BMP-2-mediated osteogenesis based on gene expression of RUNX2, the master osteogenic transcription factor, did not show any difference between control and BMP-2 stimulated BMSCs in either adult or pediatric BMSCs (data not shown) as previously described in earlier reports [3]. We further assessed gene expression levels of Osterix and MSX-2 that can be activated independent of RUNX2. In serum-free insulin-containing medium, BMP-2 enhanced MSX-2 (Figure 5A) and Osterix (Figure 5B) gene expression in adult maxilla, mandible and iliac crest BMSCs with mandible showing the highest response and Osterix mRNA much more elevated than MSX-2. In contrast, Osterix and MSX-2 mRNA levels were much lower in adult maxilla and mandible BMSCs under serum-containing culture conditions (data not shown) and there were no significant differences between expression levels of Osterix and MSX-2 in either adult or pediatric iliac crest BMSCs (Figure 5C and D).

Figure 5
BMP-2 disparately increased Osterix and MSX-1 expression in orofacial BMSCs cultured in serum-free insulin-containing medium

Discussion

We evaluated the effects of age and skeletal site-specificity on BMP-2-mediated osteogenic differentiation of human BMSCs from adult maxilla, mandible and iliac crest and pediatric iliac crest. Previously, we have established the existence of site-specific variations in the response of orofacial (maxilla and mandible) and iliac crest human BMSCs to osteogenic and adipogenic inducers in vitro as well as their in vivo bone regenerative capacity [16]. Adult orofacial BMSCs were reported to be more responsive to osteogenic inducers in vitro and regenerated quantitatively more bone in vivo. Those initial studies were confined to the use of osteogenic medium that contained ascorbic acid and dexamethasone while BMPs and other osteogenic growth factors were not tested. The current study advanced the previous work by further testing age and skeletal site-specific osteogenic response of BMSCs to BMP-2 stimulation.

The osteogenic effects and therapeutic potential of rhBMP-2 is well recognized using animal and human BMSC cultures [18]. But human BMSCs are apparently less responsive to BMP stimulation than animal cells. Our previous studies demonstrated that adult human femoral BMSCs treated with rhBMP-2 did not exhibit higher expression of either alkaline phosphatase or osteopontin under standard culture conditions but needed modifications of culture conditions before undergoing osteogenic differentiation [3]. Consistent with this report, our present study indicated that adult human iliac crest BMSCs responded like femoral cells and did not display appreciable osteogenic response to rhBMP-2. Although insulin/Insulin Growth Factor signaling pathway acts synergistically with BMP pathway in adult human mesenchymal stem cells to induce gene expression [19], adult iliac crest BMSCs were still osteogenically less responsive to rhBMP-2 stimulation when cultured in serum-free insulin-containing medium. This is consistent with similar reports on vertebral body-derived adult human BMSCs that also displayed limited osteogenic response to rhBMP-2 in a defined serum-free culture condition [20].

The minimal response of adult iliac crest BMSCs prompted further evaluation of age-related effects on BMP-2 response. The impact of age is relevant in rodents considering that BMSCs usually isolated from young animals are readily responsive to BMP stimulation. In humans, these age-related effects still need to be further clarified [2123]. The human pediatric iliac crest BMSCs evaluated in this study were more osteogenically responsive to BMP-2 stimulation than adult cells based on elevated alkaline phosphatase and osteopontin mRNA levels. These observations support the existence of age-related BMP-2 responsiveness of iliac crest BMSCs and are consistent with earlier reports that rhBMP-2 treated BMSCs from young subjects have high bone forming capacity [12, 14, 24]. However, further studies on long-term osteogenesis, effects on bone remodeling and osteoblast-osteoclast balance are still needed to fully understand the underlying mechanisms.

In contrast to the low response of adult iliac crest BMSCs, orofacial (maxilla and mandible) BMSCs displayed high expression of alkaline phosphatase and osteopontin in response to rhBMP-2. This is consistent with our previous report that orofacial BMSCs have greater osteogenic potential in culture [16] and underscores the existence of skeletal site-specificity of BMSC osteogenesis. Skeletal site-specificity of BMSCs may be due to their different embryological origins because craniofacial bones arise from neural crest while axial and appendicular bones arise from mesoderm. Similarly, craniofacial bones have dual intramembranous and endochondral ossification patterns while axial and appendicular bones undergo only endochondral ossification. During endochondral ossification, BMPs are thought to serve more as inducers of mesenchymal condensation and chondrogenic differentiation rather than bone inducers [25, 26]. On the other hand, recent studies have shown that BMPs influence differentiation of neural crest-derived mesenchyme into bone [27] and exogenous treatment of avian mandible with BMP resulted in accelerated osteogenesis [28]. It is noteworthy that BMP-2 did not alter proliferative capacity of BMSCs tested in this study (Figure 1), further highlighting that these disparate BMP-2 mediated responses were more related to BMSC differentiation and not cell number.

We assessed the possibility that disparate BMP-induced expressions of early osteogenic genes like alkaline phosphatase and osteopontin indicate age and skeletal site-specific variations in expression of three osteogenic transcription factors, namely RUNX2, MSX-2 and Osterix. BMSCs were kept in culture for 7 days in this study, so it was not surprising that mRNA levels of RUNX2, an early marker of osteoblast differentiation, remained unchanged in both pediatric and adult BMP-treated cells (data not shown) because RUNX2 expression is usually transiently elevated within the first hours of BMP treatment in adult BMSCs [25, 29]. Since actions of Osterix and MSX-2 are interrelated [3032] and BMP-2 directly regulates MSX-2 gene expression through Smad binding elements in a promoter region [33], it is possible that BMPs can indirectly activate Osterix expression through MSX-2 [32] or DLX-5 [34] without involving RUNX2, the master osteogenic transcription factor [25]. Therefore, we focused on Osterix and MSX-2 expression levels in assessing skeletal site and age-related effects on BMSCs response to BMP-2. In contrast to unchanged expression of RUNX2, induction of MSX-2 and Osterix mRNAs was sustained in response to BMP-2 stimulation. The higher levels of Osterix and MSX-2 mRNA displayed by maxilla and mandible relative to iliac crest BMSC were consistent with similarly high expressions of alkaline phosphatase and osteopontin. Therefore, adult maxilla and mandible may have responded by activation of MSX-2 and Osterix while iliac crest cells probably responded to BMP-2 by a different mechanism. Understanding these mechanisms will further illuminate age-related differences between pediatric and adult iliac crest BMSCs that displayed similar levels of MSX-2 and Osterix despite pediatric cells being more responsive to BMP-2. The small number of BMSC samples tested is one limitation of this study. But testing BMSCs from four adult and four pediatric subjects was in accordance with earlier studies that showed sample size of 4 was adequate to demonstrate statistically significant cellular response in mesenchymal stem cells obtained from different skeletal sites in same individuals [16, 17]. To minimize individual variability, maxilla, mandible and iliac crest BMSCs from each adult subject were matched so that cells from same individuals were evaluated together. Another limitation was that only pediatric iliac crest BMSCs were tested, but this decision was based on ethical guidelines of the experimental design.

In summary, this study showed that age and skeletal site-specific differences exist in BMP-2-induced BMSC osteogenesis. BMP-mediated osteogenesis of pediatric iliac crest and adult orofacial BMSCs were generally higher than adult iliac crest cells. Our results suggest that Osterix and MSX-2 are potential regulatory transcription factors in BMP-mediated osteogenesis of adult orofacial cells. Further elucidation of underlying mechanisms of this disparate BMP-2 response is still needed.

Acknowledgments

The authors thank Dr. D. LaRossa, Division of Plastic and Reconstructive Surgery, Department of Pediatric Plastic Surgery, Children’s Hospital of Philadelphia for pediatric bone marrow samples and appreciate the support of Dr. Phoebe Leboy, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA. Funding for this study was provided in part by DHHS/NIH grants 5-R03-AG-026047-02 and 1K08CA120875-01 awarded to S.O.A and MIRG-CT-2007-046479 grant within EC 6FP and 465/6.PRUE/2007/7 subsidiary financing from Polish Ministry of Science and Education awarded to A.M.O.

References

1. Andrades JA, Santamaria JA, Nimni ME, Becerra J. Selection and amplification of a bone marrow cell population and its induction to the chondro-osteogenic lineage by rhOP-1: an in vitro and in vivo study. Int J Dev Biol. 2001;45:689–693. [PubMed]
2. Cheng SL, Yang JW, Rifas L, Zhang SF, Avioli LV. Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone. Endocrinology. 1994;134:277–286. [PubMed]
3. Osyczka AM, Leboy PS. Bone morphogenetic protein regulation of early osteoblast genes in human marrow stromal cells is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling. Endocrinology. 2005;146:3428–3437. [PMC free article] [PubMed]
4. Bonn D. The application of cell biology to broken bones. Lancet. 1999;353:650. [PubMed]
5. Wang EA, Rosen V, D’Alessandro JS, Bauduy M, Cordes P, Harada T, Israel DI, et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A. 1990;87:2220–2224. [PubMed]
6. Fromigue O, Marie PJ, Lomri A. Bone morphogenetic protein-2 and transforming growth factor-beta2 interact to modulate human bone marrow stromal cell proliferation and differentiation. J Cell Biochem. 1998;68:411–426. [PubMed]
7. Rickard DJ, Sullivan TA, Shenker BJ, Leboy PS, Kazhdan I. Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2. Dev Biol. 1994;161:218–228. [PubMed]
8. Thies RS, Bauduy M, Ashton BA, Kurtzberg L, Wozney JM, Rosen V. Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology. 1992;130:1318–1324. [PubMed]
9. Cowan CM, Aalami OO, Shi YY, Chou YF, Mari C, Thomas R, Quarto N, et al. Bone morphogenetic protein 2 and retinoic acid accelerate in vivo bone formation, osteoclast recruitment, and bone turnover. Tissue Eng. 2005;11:645–658. [PubMed]
10. Diefenderfer DL, Osyczka AM, Garino JP, Leboy PS. Regulation of BMP-induced transcription in cultured human bone marrow stromal cells. J Bone Joint Surg Am. 2003;85-A(Suppl 3):19–28. [PMC free article] [PubMed]
11. Diefenderfer DL, Osyczka AM, Reilly GC, Leboy PS. BMP responsiveness in human mesenchymal stem cells. Connect Tissue Res. 2003;44(Suppl 1):305–311. [PubMed]
12. Yamagiwa H, Endo N, Tokunaga K, Hayami T, Hatano H, Takahashi HE. In vivo bone-forming capacity of human bone marrow-derived stromal cells is stimulated by recombinant human bone morphogenetic protein-2. J Bone Miner Metab. 2001;19:20–28. [PubMed]
13. Welch RD, Jones AL, Bucholz RW, Reinert CM, Tjia JS, Pierce WA, Wozney JM, et al. Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. Journal of Bone & Mineral Research. 1998;13:1483–1490. [PubMed]
14. Volk SW, Diefenderfer DL, Christopher SA, Haskins ME, Leboy PS. Effects of osteogenic inducers on cultures of canine mesenchymal stem cells. Am J Vet Res. 2005;66:1729–1737. [PubMed]
15. Osyczka AM, Diefenderfer DL, Bhargave G, Leboy PS. Different effects of BMP-2 on marrow stromal cells from human and rat bone. Cells Tissues Organs. 2004;176:109–119. [PMC free article] [PubMed]
16. Akintoye SO, Lam T, Shi S, Brahim J, Collins MT, Robey PG. Skeletal site-specific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. Bone. 2006;38:758–768. [PubMed]
17. Stefanik D, Sarin J, Lam T, Levin L, Leboy PS, Akintoye SO. Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis. 2008;14:465–471. [PMC free article] [PubMed]
18. Kirker-Head CA, Boudrieau RJ, Kraus KH. Use of bone morphogenetic proteins for augmentation of bone regeneration. J Am Vet Med Assoc. 2007;231:1039–1055. [PubMed]
19. Celil AB, Campbell PG. BMP-2 and insulin-like growth factor-I mediate Osterix (Osx) expression in human mesenchymal stem cells via the MAPK and protein kinase D signaling pathways. J Biol Chem. 2005;280:31353–31359. [PubMed]
20. Friedman MS, Long MW, Hankenson KD. Osteogenic differentiation of human mesenchymal stem cells is regulated by bone morphogenetic protein-6. J Cell Biochem. 2006;98:538–554. [PubMed]
21. Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008;129:163–173. [PubMed]
22. Tokalov SV, Gruener S, Schindler S, Iagunov AS, Baumann M, Abolmaali ND. A number of bone marrow mesenchymal stem cells but neither phenotype nor differentiation capacities changes with age of rats. Mol Cells. 2007;24:255–260. [PubMed]
23. Zhang W, Ou G, Hamrick M, Hill W, Borke J, Wenger K, Chutkan N, et al. Age-related changes in the osteogenic differentiation potential of mouse bone marrow stromal cells. J Bone Miner Res. 2008;23:1118–1128. [PubMed]
24. Matsumoto A, Yamaji K, Kawanami M, Kato H. Effect of aging on bone formation induced by recombinant human bone morphogenetic protein-2 combined with fibrous collagen membranes at subperiosteal sites. J Periodontal Res. 2001;36:175–182. [PubMed]
25. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2002;2:389–406. [PubMed]
26. Tsumaki N, Yoshikawa H. The role of bone morphogenetic proteins in endochondral bone formation. Cytokine Growth Factor Rev. 2005;16:279–285. [PubMed]
27. Abzhanov A, Rodda SJ, McMahon AP, Tabin CJ. Regulation of skeletogenic differentiation in cranial dermal bone. Development. 2007;134:3133–3144. [PubMed]
28. Merrill AE, Eames BF, Weston SJ, Heath T, Schneider RA. Mesenchyme-dependent BMP signaling directs the timing of mandibular osteogenesis. Development. 2008;135:1223–1234. [PMC free article] [PubMed]
29. Kim IS, Song YM, Cho TH, Park YD, Lee KB, Noh I, Weber F, et al. In vitro response of primary human bone marrow stromal cells to recombinant human bone morphogenic protein-2 in the early and late stages of osteoblast differentiation. Dev Growth Differ 2008 [PubMed]
30. Cheng SL, Shao JS, Charlton-Kachigian N, Loewy AP, Towler DA. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem. 2003;278:45969–45977. [PubMed]
31. Kurata H, Guillot PV, Chan J, Fisk NM. Osterix induces osteogenic gene expression but not differentiation in primary human fetal mesenchymal stem cells. Tissue Eng. 2007;13:1513–1523. [PubMed]
32. Matsubara T, Kida K, Yamaguchi A, Hata K, Ichida F, Meguro H, Aburatani H, et al. BMP2 Regulates Osterix through Msx2 and Runx2 during Osteoblast Differentiation. J Biol Chem. 2008;283:29119–29125. [PMC free article] [PubMed]
33. Brugger SM, Merrill AE, Torres-Vazquez J, Wu N, Ting MC, Cho JY, Dobias SL, et al. A phylogenetically conserved cis-regulatory module in the Msx2 promoter is sufficient for BMP-dependent transcription in murine and Drosophila embryos. Development. 2004;131:5153–5165. [PubMed]
34. Ulsamer A, Ortuno MJ, Ruiz S, Susperregui AR, Osses N, Rosa JL, Ventura F. BMP-2 induces Osterix expression through up-regulation of Dlx5 and its phosphorylation by p38. J Biol Chem. 2008;283:3816–3826. [PubMed]